1 March 2019
EMA/PDCO/56017/2019
Inspections, Human Medicines Pharmacovigilance and Committees Division

Paediatric Committee (PDCO)

Minutes of the meeting on 29 January - 01 February 2019

Chair: Dirk Mentzer – Vice-Chair: Koenraad Norga

29 January 2019, 14:00- 19:00, room 3A

30 January 2019, 08:30- 19:00, room 3A

31 January 2019, 08:30- 19:00, room 3A

01 February 2019, 08:30- 13:00, room 3A

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes.

Further information with relevant explanatory notes can be found at the end of this document.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Table of contents

1. Introductions 9

1.1. Welcome and declarations of interest of members, alternates and experts 9

1.2. Adoption of agenda 9

1.3. Adoption of the minutes 9

2. Opinions 9

2.1. Opinions on Products 9

2.1.1. Mavacamten - EMEA-002231-PIP01-17 9

2.1.2. Dihomo-γ-linolenic acid (DGLA) - EMEA-002364-PIP02-18 10

2.1.3. Chemically modified recombinant human sulfamidase - Orphan - EMEA-002380-PIP01-18 10

2.1.4. (6aR,10aR)-1-Hydroxy-6,6-dimethyl-3-(2-methyl-2-octanyl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene-9-carboxylic acid - Orphan - EMEA-002069-PIP02-17 10

2.1.5. Guselkumab - EMEA-001523-PIP03-18 11

2.1.6. 1-{[(2S,3S)-2-carboxylato-3-methyl-4,4,7-trioxo-4-{6}-thia-1-azabi-cyclo[3.2.0]heptan-3-yl]methyl}-3-methyl-1H-1,2,3-triazol-3-ium - EMEA-002240-PIP02-17 11

2.1.7. Pretomanid - Orphan - EMEA-002115-PIP01-17 11

2.1.8. Ridinilazole - EMEA-002250-PIP02-17 11

2.1.9. Isoflurane - EMEA-002320-PIP01-17 12

2.1.10. Avapritinib - Orphan - EMEA-002358-PIP02-18 12

2.1.11. Spartalizumab - EMEA-002351-PIP01-18 12

2.1.12. (R)-azasetron (as besylate) - Orphan - EMEA-002165-PIP02-18 13

2.1.13. Ivacaftor / tezacaftor / N-(1,3-dimethyl-1H-pyrazole-4-sulfonyl)-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide - EMEA-002324-PIP01-17 13

2.1.14. Ivacaftor / tezacaftor / potassium (benzenesulfonyl)({[6-(3-{2-[1-(trifluoromethyl)cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridin-3-yl]carbonyl})azanide - EMEA-002191-PIP02-17 13

2.1.15. Molgramostim - Orphan - EMEA-002282-PIP01-17 14

2.1.16. Recombinant Influenza Hemagglutinin-strain B (Yamagata lineage) / Recombinant Influenza Hemagglutinin-strain B (Victoria lineage) / Recombinant Influenza Hemagglutinin-strain A (H3N2 subtype) / Recombinant Influenza Hemagglutinin-strain A (H1N1 subtype) - EMEA-002418-PIP01-18 14

2.1.17. Amlodipine besylate / rosuvastatin calcium - EMEA-002456-PIP01-18 14

2.1.18. N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl) pyridin-2-yl) acetamide - EMEA-002470-PIP01-18 15

2.1.19. Norethisterone acetate / estradiol / relugolix - EMEA-002428-PIP01-18 15

2.1.20. Pyrimidinyl-aminopyridine dual leucine zipper kinase inhibitor - EMEA-002469-PIP02-18 . 15

2.1.21. Genetically modified Mycobacterium bovis BCG - EMEA-002461-PIP01-18 15
2.1.22. Empagliflozin - EMEA-000828-PIP06-18..... 16
2.1.23. Upadacitinib - EMEA-001741-PIP06-18 16
2.2. Opinions on Compliance Check 17
2.2.1. Avibactam / ceftazidime - EMEA-C2-001313-PIP01-12-M08 17
2.2.2. Pembrolizumab - EMEA-C-001474-PIP01-13-M01 17
2.2.3. Rituximab - EMEA-C-000308-PIP02-11-M01..... 17
2.2.4. Rabeprazole (sodium) - EMEA-C-000055-PIP01-07-M06 17
2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan 18
2.3.1. Ambrisentan - Orphan - EMEA-000434-PIP01-08-M05..... 18
2.3.2. Tralokinumab - EMEA-001900-PIP02-17-M02..... 18
2.3.3. Alogliptin benzoate (as alogliptin) - EMEA-000496-PIP01-08-M06 18
2.3.4. Avalglucosidase alfa - Orphan - EMEA-001945-PIP01-16-M01 19
2.3.5. Tofacitinib - EMEA-000576-PIP03-12-M02..... 19
2.3.6. Ustekinumab - EMEA-000311-PIP04-13-M01..... 19
2.3.7. Crizanlizumab - Orphan - EMEA-002141-PIP01-17-M01..... 20
2.3.8. Apremilast - EMEA-000715-PIP02-11-M03 20
2.3.9. Isavuconazonium (sulfate) - Orphan - EMEA-001301-PIP02-12-M03 20
2.3.10. EMEA-001838-PIP01-15-M02 20
2.3.11. Lefamulin - EMEA-002075-PIP01-16-M01 21
2.3.12. Erenumab - EMEA-001664-PIP02-15-M03..... 21
2.3.13. Galcanezumab - EMEA-001860-PIP03-16-M02 21
2.3.14. Satralizumab (humanised anti-IL-6 receptor (IL-6R) monoclonal antibody) - Orphan - EMEA-001625-PIP01-14-M02 22
2.3.15. Lacosamide - EMEA-000402-PIP03-17-M03..... 22
2.3.16. Peginterferon beta-1a - EMEA-001129-PIP01-11-M03 22
2.3.17. Acalabrutinib - Orphan - EMEA-001796-PIP03-16-M01 23
2.3.18. Dabrafenib mesylate - EMEA-001147-PIP01-11-M06 23
2.3.19. Carotuximab - Orphan - EMEA-002138-PIP01-17-M01..... 23
2.3.20. Olaratumab - Orphan - EMEA-001760-PIP01-15-M03 24
2.3.21. Rituximab - EMEA-000308-PIP01-08-M04..... 24
2.3.22. Trametinib dimethyl sulfoxide - EMEA-001177-PIP01-11-M05 24
2.3.23. Eltrombopag (eltrombopag olamine) - EMEA-000170-PIP02-10-M03 25
2.3.24. Autologous cartilage derived cultured chondrocytes - EMEA-001823-PIP01-15-M01 25
2.3.25. Methoxyflurane - EMEA-000334-PIP01-08-M08 25
2.3.26. Chemically modified extract of grass pollen from Holcus lanatus, Phleum pratense and Poa pratensis - EMEA-001016-PIP01-10-M01 26
2.3.27. Chemically modified extract of grass pollen from Holcus lanatus, Phleum pratense and Poa pratensis - EMEA-001017-PIP01-10-M01 26

2.3.28. Chemically modified extract of trees pollen from Birch and Alder - EMEA-001012-PIP01-10-M01 26
2.3.29. Chemically modified extract of trees pollen from Birch and Alder - EMEA-001013-PIP01-10-M01 26
2.3.30. Chemically modified house dust mites allergen extract of Dermatophagoides pteronyssinus and Dermatophagoides farinae - EMEA-001011-PIP01-10-M01 27
2.3.31. Chemically modified house dust mites allergen extract of Dermatophagoides pteronyssinus and Dermatophagoides farinae - EMEA-001014-PIP01-10-M01 27
2.3.32. Neisseria meningitidis serogroup B recombinant lipoprotein (subfamily B; Escherichia coli) / Neisseria meningitidis serogroup B recombinant lipoprotein (subfamily A; Escherichia coli) - EMEA-001037-PIP02-11-M05 27
2.3.33. Upadacitinib - EMEA-001741-PIP02-16-M01 28
2.3.34. Upadacitinib - EMEA-001741-PIP03-16-M01 28
2.3.35. Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H3N2) / Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Yamagata lineage) / Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Victoria lineage) / Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H1N1) (EMEA-001715-PIP01-14-M02) 28
2.4. Opinions on Re-examinations 28
2.4.1. Empagliflozin - EMEA-000828-PIP04-16-M02 28
2.5. Opinions on Review of Granted Waivers 29
2.6. Finalisation and adoption of opinions 29
2.7. Partial Compliance Checks completed by EMA 29
2.7.1. Pembrolizumab - EMEA-C1-001474-PIP02-16-M01 29
2.7.2. Venetoclax - EMEA-C1-002018-PIP02-16-M01 29
2.7.3. Edoxaban (tosylate) - EMEA-C3-000788-PIP02-11-M08 29
2.7.4. Baricitinib - EMEA-C1-001220-PIP03-16 30
2.7.5. Eculizumab - EMEA-C1-000876-PIP03-14-M02 30
3. Discussion of applications 30
3.1. Discussions on Products D90-D60-D30 30
3.1.1. EMEA-002378-PIP01-18 30
3.1.2. Hepcidin-25 acetate (synthetic human hepcidin) - Orphan - EMEA-002083-PIP01-16 31
3.1.3. EMEA-001710-PIP03-17 31
3.1.4. EMEA-002374-PIP01-18 31
3.1.5. Voclosporin - EMEA-002264-PIP01-17 31
3.1.6. Oteseconazole - EMEA-002392-PIP01-18 31
3.1.7. Ofatumumab - EMEA-002397-PIP01-18 31
3.1.8. Abemaciclib - EMEA-002342-PIP01-18 31
3.1.9. EMEA-002348-PIP01-18 32

3.1.10. Autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector encoding a chimeric antigen receptor targeting human B cell maturation antigen with 4-1BB and CD3-zeta intracellular signaling domains - Orphan - EMEA-002369-PIP01-18 32
3.1.11. Vinorelbine tartrate (liposomal) - EMEA-002365-PIP01-18 32
3.1.12. Aflibercept - EMEA-000236-PIP05-18 32
3.1.13. Nintedanib - Orphan - EMEA-001006-PIP05-18 32
3.1.14. EMEA-002307-PIP01-17 33
3.1.15. EMEA-002308-PIP01-17 33
3.1.16. EMEA-002451-PIP01-18 33
3.1.17. EMEA-002464-PIP01-18 33
3.1.18. Trifarotene cream HE1 - EMEA-001492-PIP02-18 33
3.1.19. EMEA-002448-PIP01-18 33
3.1.20. C1 esterase inhibitor (human) - EMEA-000568-PIP02-18 33
3.1.21. Liposomal ciclosporin A (L-CsA) - Orphan - EMEA-002344-PIP02-18 34
3.1.22. Baloxavir marboxil - EMEA-002440-PIP01-18 34
3.1.23. Hydrocortisone - EMEA-002305-PIP01-17 34
3.1.24. Padsevonil - EMEA-002466-PIP01-18 34
3.1.25. Larotrectinib - Orphan - EMEA-001971-PIP03-18 34
3.1.26. Marizomib - EMEA-002452-PIP01-18 34
3.1.27. aldesleukin - EMEA-002492-PIP01-18 35
3.1.28. Zanubrutinib - EMEA-002354-PIP02-18 35
3.1.29. Pneumococcal Polyssacharide Serotype 33F conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 23F conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 22F conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 19F conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 19A conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 18C conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 15B conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 14 conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 12F conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 11A conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 10A conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 9V conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 8 conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 7F conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 6B conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 6A conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 5 conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 4 conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 3 conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate /

Pneumococcal Polyssacharide Serotype 1 conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate - EMEA-002330-PIP01-18 36
3.1.30. Recombinant respiratory syncytial virus fusion (RSV F) glycoprotein - EMEA-001985-PIP01-18 36
3.1.31. Rosuvastatin calcium / fenofibrate - EMEA-002509-PIP01-18 36
3.1.32. EMEA-002481-PIP01-18 37
3.1.33. Serlopitant - EMEA-002496-PIP01-18 37
3.1.34. Gadopiclenol - EMEA-001949-PIP02-18 37
3.1.35. Levonorgestrel - EMEA-002474-PIP02-18 37
3.1.36. Norursodeoxycholic acid - Orphan - EMEA-002485-PIP01-18 37
3.1.37. AAV2/S3-FRE1-TI-FIXco1 vector - Orphan - EMEA-002518-PIP01-18 37
3.1.38. Recombinant human monoclonal antibody against mannan-binding lectin-associated serine protease-2 - Orphan - EMEA-002479-PIP01-18 37
3.1.39. Anti-CD7 mAb conjugated to ricin toxin A chain (WT1-RTA) / anti-CD3 mAb conjugated to ricin toxin A chain (SPV-T3a-RTA) - Orphan - EMEA-002087-PIP01-16 38
3.1.40. Secukinumab - EMEA-000380-PIP05-18 38
3.1.41. Artesunate - Orphan - EMEA-002402-PIP02-18 38
3.1.42. Delafloxacin - EMEA-001080-PIP03-18 38
3.1.43. Equine Immunoglobulin F(ab')2 fragments targeting Shiga toxin - Orphan - EMEA-002444-PIP02-18 38
3.1.44. Tazobactam sodium / cefepime hydrochloride - EMEA-002483-PIP01-18 38
3.1.45. EMEA-002419-PIP02-18 39
3.1.46. Crizotinib - EMEA-001493-PIP03-18 39
3.1.47. Flucytosine - Orphan - EMEA-002437-PIP02-18 39
3.1.48. L-asparaginase - Orphan - EMEA-000341-PIP03-18 39
3.1.49. Rivoceranib mesylate - Orphan - EMEA-002489-PIP01-18 39
3.1.50. Rogaratinib - EMEA-002439-PIP01-18 39
3.1.51. EMEA-002504-PIP01-18 40
3.1.52. Tislelizumab - EMEA-002480-PIP01-18 40
3.1.53. Vocimagene amiretrorepvec - Orphan - EMEA-002505-PIP02-18 40
3.1.54. Cenergermin - Orphan - EMEA-001729-PIP02-18 40
3.1.55. EMEA-002484-PIP01-18 40
3.1.56. Orvepitant - EMEA-002510-PIP01-18 40
3.1.57. Synthetic double-stranded siRNA oligonucleotide directed against lactate dehydrogenase A mRNA and containing four modified nucleosides which form a ligand cluster of four N-acetylgalactosamine residues - Orphan - EMEA-002493-PIP01-18 41
3.2. Discussions on Compliance Check 41
3.2.1. Sebelipase alfa - EMEA-C-001331-PIP01-12-M02 41
3.2.2. Denosumab - EMEA-C-000145-PIP01-07-M09 41
3.2.3. Conestat Alfa - EMEA-C-000367-PIP01-08-M08 41

3.2.4. Peanut allergen extract - EMEA-C1-001481-PIP01-13-M03 41
3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan 41
3.3.1. Corifollitropin alfa - EMEA-000306-PIP01-08-M04 41
3.3.2. Rivaroxaban - EMEA-000430-PIP01-08-M11 42
3.3.3. Ertugliflozin L-PGA - EMEA-001533-PIP01-13-M02 42
3.3.4. Migalstat hydrochloride - Orphan - EMEA-001194-PIP01-11-M04 42
3.3.5. Recombinant parathyroid hormone: rhPTH (1-84) - Orphan - EMEA-001526-PIP01-13-M03 42
3.3.6. Luspatercept - Orphan - EMEA-001521-PIP01-13-M03 42
3.3.7. Nonacog beta pegol (glycopegylated recombinant coagulation factor IX) - Orphan - EMEA-000731-PIP01-09-M03 42
3.3.8. Roxadustat - EMEA-001557-PIP01-13-M03 43
3.3.9. Tofacitinib citrate - EMEA-000576-PIP01-09-M10 43
3.3.10. Ceftolozane / tazobactam - EMEA-001142-PIP01-11-M03 43
3.3.11. Etravirine - EMEA-000222-PIP01-08-M09 43
3.3.12. Oritavancin diphosphate - EMEA-001270-PIP01-12-M02 43
3.3.13. Inebilizumab - Orphan - EMEA-001911-PIP01-15-M02 43
3.3.14. Teriflunomide - EMEA-001094-PIP01-10-M05 44
3.3.15. Regorafenib - EMEA-001178-PIP01-11-M04 44
3.3.16. Idarucizumab - EMEA-001438-PIP01-13-M01 44
3.3.17. Selexipag - EMEA-000997-PIP01-10-M02 44
3.3.18. Fevipiprant - EMEA-001315-PIP02-16-M01 44
3.3.19. Peanut flour - EMEA-001734-PIP01-14-M04 44
3.3.20. Neisseria meningitidis serogroup Y polysaccharide conjugated to tetanus toxoid / Neisseria meningitidis serogroup W-135 polysaccharide conjugated to tetanus toxoid / Neisseria meningitidis serogroup C polysaccharide conjugated to tetanus toxoid / Neisseria meningitidis serogroup A polysaccharide conjugated to tetanus toxoid - EMEA-001930-PIP01-16-M01 . 45
4. Nominations 45
4.1. List of letters of intent received for submission of applications with start of procedure 01 April 2019 for Nomination of Rapporteur and Peer reviewer 45
4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver. 45
4.3. Nominations for other activities 45
5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction 45
5.1. New Scientific Advice 45
5.2. Ongoing Scientific Advice 46
5.3. Final Scientific Advice (Reports and Scientific Advice letters) 46
6. Discussion on the applicability of class waivers 46
6.1. Discussions on the applicability of class waiver for products 46

6.1.1. Humanized anti-tau monoclonal antibody-EMEA-17-2018 46

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver 46

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver 46

8. Annual reports on deferrals 46

9. Organisational, regulatory and methodological matters 46

9.1. Mandate and organisation of the PDCO 46

9.1.1. PDCO Mandate 46

9.2. Coordination with EMA Scientific Committees or CMDh-v 47

9.2.1. Committee for Medicinal Products for Human Use (CHMP) 47

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups 47

9.3.1. Non-clinical Working Group: D30 Products identified 47

9.3.2. Formulation Working Group 47

9.3.3. Patients' and Consumers' Organisations (PCWP) and Healthcare Professionals' Organisations (HCPWP) 47

9.4. Cooperation within the EU regulatory network 48

9.4.1. European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA) 48

9.5. Cooperation with International Regulators 48

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee 48

9.7. PDCO work plan 48

9.8. Planning and reporting 48

10. Any other business 48

11. Breakout sessions 48

11.1.1. Paediatric oncology 48

11.1.2. Neonatology 48

11.1.3. Inventory 48

11.1.4. Systemic lupus erythematosus 49

12. List of participants 50

13. Explanatory notes 54

1. Introductions

1.1. Welcome and declarations of interest of members, alternates and experts

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions as included in the pre-meeting list of participants and restrictions.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 23 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

The agenda was adopted and published on the EMA website.

1.3. Adoption of the minutes

The minutes of the December 2018 PDCO meeting were adopted and published on the EMA website.

2. Opinions

Some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

2.1. Opinions on Products

2.1.1. Mavacamten - EMEA-002231-PIP01-17

MyoKardia, Inc.; Treatment of Hypertrophic Cardiomyopathy / Treatment of obstructive Hypertrophic Cardiomyopathy

Day 120 Opinion

Cardiovascular Diseases

Summary of committee discussion:

The Committee adopted a positive Opinion for mavacamten for the 'Treatment of

hypertrophic cardiomyopathy' including a deferral.

2.1.2. Dihomo-γ-linolenic acid (DGLA) - EMEA-002364-PIP02-18

DS Biopharma Ltd.; Treatment of atopic dermatitis / Treatment of mild to moderate atopic dermatitis, Treatment of mild to moderate atopic dermatitis with steroid-sparing effects

Day 120 Opinion

Dermatology

Summary of committee discussion:

The PDCO considered the Applicant's responses acceptable.
Having assessed the proposed paediatric investigation plan, the Committee adopted by majority a positive Opinion granting a deferral. Twenty-four members voted in favour of the Opinion whilst six members had divergent views[1]. The Norwegian PDCO member agreed with the Opinion.

2.1.3. Chemically modified recombinant human sulfamidase - Orphan - EMEA-002380-PIP01-18

Swedish Orphan Biovitrum AB (publ); Mucopolysaccharidosis type IIIA (MPS IIIA)

Day 120 Opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

Following receipt of the Applicant's responses to Day 90 PDCO questions and further exchange with the Applicant, there were issues remaining that were discussed during an oral explanation.
The PDCO adopted a positive Opinion for chemically modified recombinant human sulfamidase for all subsets of the paediatric population (0 to 18 years of age) in the condition of Mucopolysaccharidosis type IIIA (MPS IIIA).

2.1.4. (6aR,10aR)-1-Hydroxy-6,6-dimethyl-3-(2-methyl-2-octanyl)-6a,7,10,10a-tetrahydro-6H-benzo[c]chromene-9-carboxylic acid - Orphan - EMEA-002069-PIP02-17

Corbus Pharmaceuticals Holdings Inc; Treatment of systemic sclerosis

Day 120 Opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

Based on the assessment of this application and further discussions at the January 2019 meeting taking into account that the Applicant had addressed almost all the points raised at Day 90, the PDCO agreed with the Applicant's request for a PIP with a deferral for the treatment of systemic sclerosis for (6aR,10aR)-1-Hydroxy-6,6-dimethyl-3-(2-methyl-2-octanyl)-6a,7,10,10a-tetrahydro-6H-

[1] Irja Lutsar, Sylvie Benchetrit, Dimitar Roussinov, Angeliki Siapkara, Fernando de Andre Trelles, Sabine Scherer

benzo[c]chromene-9-carboxylic acid (lenabasum) and, therefore, agreed a positive Opinion.

2.1.5. Guselkumab - EMEA-001523-PIP03-18

Janssen-Cilag International NV; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, spondyloarthritis, PsA and juvenile idiopathic arthritis [JIA]) / Treatment of juvenile idiopathic arthritis (juvenile psoriatic arthritis [jPsA])

Day 120 Opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

The Applicant had provided satisfactory responses to the PDCO's requests from Day 90. The Committee adopted a positive Opinion on this PIP for the treatment of chronic idiopathic arthritis.

2.1.6. 1-{[(2S,3S)-2-carboxylato-3-methyl-4,4,7-trioxo-4-{6}-thia-1-azabi-cyclo[3.2.0]heptan-3-yl]methyl}-3-methyl-1H-1,2,3-triazol-3-ium - EMEA-002240-PIP02-17

Allecra Therapeutics GmbH; Treatment of Urinary Tract Infections

Day 120 Opinion

Infectious Diseases

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed on a positive Opinion for 1-{[(2S,3S)-2-carboxylato-3-methyl-4,4,7-trioxo-4-{6}-thia-1-azabi-cyclo[3.2.0]heptan-3-yl]methyl}-3-methyl-1H-1,2,3-triazol-3-ium for all subsets of the paediatric population (0 to 18 years of age) in the condition of 'Treatment of Urinary Tract Infections'.

2.1.7. Pretomanid - Orphan - EMEA-002115-PIP01-17

Global Alliance for TB Drug Development; Treatment of multidrug-resistant tuberculosis

Day 120 Opinion

Infectious Diseases

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed on a positive Opinion for pretomanid for all subsets of the paediatric population less than 18 years of age in the condition of 'Treatment of multi-drug-resistant tuberculosis'.

2.1.8. Ridinilazole - EMEA-002250-PIP02-17

Summit (Oxford) Limited; Clostridium difficile Infection (CDI) and recurrence of CDI / Treatment of Clostridium difficile Infection (CDI) and reducing the recurrence of CDI

Day 120 opinion

Infectious Diseases

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed on a positive Opinion for ridinilazole for all subsets of the paediatric population from birth to less than 18 years of age in the condition of 'Treatment of Clostridium difficile Infection (CDI)'.

2.1.9. Isoflurane - EMEA-002320-PIP01-17

Sedana Medical AB; Sedation

Day 120 Opinion

Neonatology - Paediatric Intensive Care

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the Applicant's request.
The positive PIP Opinion was based on the responses to the requests for modification, including those responses received between Day 90 and Day 120.

2.1.10. Avapritinib - Orphan - EMEA-002358-PIP02-18

Blueprint Medicines (Netherlands) B.V.; Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms) / Treatment of paediatric patients with advanced solid tumors harboring mutations in either KIT or PDGFRα.

Day 120 Opinion

Oncology

Summary of committee discussion:

The PDCO's views expressed at Day 90 were endorsed and the Opinion was finalised.
In conclusion, the PDCO adopted a positive Opinion for avapritinib for the treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms) with a deferral.

2.1.11. Spartalizumab - EMEA-002351-PIP01-18

Novartis Europharm Limited; Treatment of melanoma / Treatment of adolescent patients with melanoma containing BRAF V600 activating mutations

Day 120 Opinion

Oncology

Summary of committee discussion:

The PDCO discussed the application. Overall, a positive Opinion was adopted.

2.1.12. (R)-azasetron (as besylate) - Orphan - EMEA-002165-PIP02-18

Sensorion SA; Ototoxicity, poisoning due to cisplatin, Sudden sensorineural hearing loss / Treatment of sudden sensorineural hearing loss, Prevention of cisplatin-induced ototoxicity

Day 120 Opinion

Oto-rhino-laryngology

Summary of committee discussion:

Based on the assessment of this application and further input from the Applicant, the PDCO at its January 2019 meeting agreed with the Applicant's request for a PIP ' with a deferral. A positive Opinion was adopted.

2.1.13. Ivacaftor / tezacaftor / N-(1,3-dimethyl-1H-pyrazole-4-sulfonyl)-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide - EMEA-002324-PIP01-17

Vertex Pharmaceuticals (Europe) Ltd; Treatment of Cystic Fibrosis

Day 120 Opinion

Pneumology - Allergology

Summary of committee discussion:

The PDCO discussed the paediatric programme taking into account the supplementary information submitted between Day 90 and Day 120.
Based on the assessment of this application and further discussions at the Paediatric Committee meetings, the PDCO adopted a positive Opinion for ivacaftor / tezacaftor / N-(1,3-dimethyl-1H-pyrazole-4-sulfonyl)-6-[3-(3,3,3-trifluoro-2,2-dimethylpropoxy)-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide in the condition 'Treatment of Cystic Fibrosis'.

2.1.14. Ivacaftor / tezacaftor / potassium (benzenesulfonyl)({[6-(3-{2-[1-(trifluoromethyl)cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridin-3-yl]carbonyl})azanide - EMEA-002191-PIP02-17

Vertex Pharmaceuticals (Europe) Ltd; Treatment of Cystic Fibrosis

Day 120 Opinion

Pneumology - Allergology

Summary of committee discussion:

The PDCO discussed the paediatric programme taking into account the supplementary information submitted between Day 90 and Day 120.
Based on the assessment of this application and further discussions at the Paediatric Committee meetings, the PDCO adopted a positive Opinion for ivacaftor / tezacaftor / potassium (benzenesulfonyl)({[6-(3-{2-[1-(trifluoromethyl)cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-2-

[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridin-3-yl]carbonyl})azanide in the condition 'Treatment of Cystic Fibrosis'.

2.1.15. Molgramostim - Orphan - EMEA-002282-PIP01-17

Savara ApS; Treatment of pulmonary alveolar proteinosis / Treatment of children from 6 to less than 18 years with autoimmune pulmonary alveolar proteinosis

Day 120 Opinion

Pneumology - Allergology

Summary of committee discussion:

The responses from the Applicant were considered satisfactory.
Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the Applicant's request. A PIP was agreed in the indication 'autoimmune pulmonary alveolar proteinosis'.

2.1.16. Recombinant Influenza Hemagglutinin-strain B (Yamagata lineage) / Recombinant Influenza Hemagglutinin-strain B (Victoria lineage) / Recombinant Influenza Hemagglutinin-strain A (H3N2 subtype) / Recombinant Influenza Hemagglutinin-strain A (H1N1 subtype) - EMEA-002418-PIP01-18

Sanofi Pasteur; prevention of influenza infection

Day 120 Opinion

Vaccines

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed with the Applicant's request. A PIP was agreed.

2.1.17. Amlodipine besylate / rosuvastatin calcium - EMEA-002456-PIP01-18

Abbott Laboratories Limited; Treatment of hypertension, Treatment of dyslipidemia, Treatment of ischemic coronary artery disorders, Prevention of cardiovasular events

Day 60 Opinion

Cardiovascular Diseases

Summary of committee discussion:

Based on the assessment of this application, the PDCO agrees with the Applicant's request for a waiver. The Committee recommends granting a waiver for amlodipine besylate / rosuvastatin calcium for all subsets of the paediatric population (0 to 18 years of age) on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments in the following conditions:
- 'Treatment of Hypertension'
- 'Treatment of dyslipidaemia'
- 'Treatment of ischemic coronary artery disorders'
- 'Prevention of cardiovascular events'.

2.1.18. N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl) pyridin-2-yl) acetamide - EMEA-002470-PIP01-18

Almirall S.A.; Actinic Keratosis in adults

Day 60 Opinion

Dermatology

Summary of committee discussion:

Based on the assessment of this application, the PDCO agrees with the Applicant's request for a waiver. The PDCO recommends granting a waiver for all subsets of the paediatric population (0 to 18 years of age) in the condition of 'actinic keratosis in adults'.

2.1.19. Norethisterone acetate / estradiol / relugolix - EMEA-002428-PIP01-18

Myovant Sciences Ireland Limited; uterine fibroids / treatment of symptoms associated with uterine fibroids

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

Based on the assessment of this application, the PDCO agrees with the Applicant's request for a waiver. The PDCO recommends granting a waiver for estradiol / norethisterone acetate / relugolix for all subsets of the paediatric population (birth to 18 years of age) in the condition of 'treatment of leiomyoma of uterus'.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the Applicant from considering a development in the paediatric population in indications where there is a paediatric need.

2.1.20. Pyrimidinyl-aminopyridine dual leucine zipper kinase inhibitor - EMEA-002469-PIP02-18

Roche Registration GmbH; Treatment of amyotrophic lateral sclerosis

Day 60 opinion

Neurology

Summary of committee discussion:

The PDCO's view expressed at Day 30 was re-discussed. The Committee adopted a negative Opinion rejecting a product-specific waiver for the 'Treatment of amyotrophic lateral sclerosis'.

2.1.21. Genetically modified Mycobacterium bovis BCG - EMEA-002461-PIP01-18

medac Gesellschaft für klinische Spezialpräparate mbH; Non-muscle invasive bladder cancer

Day 60 Opinion

Oncology

Summary of committee discussion:

The PDCO discussed this procedure at Day 60 during the January 2019 plenary. Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the Applicant's request for a waiver. The PDCO recommends granting a waiver for genetically modified Mycobacterium bovis BCG for all subsets of the paediatric population (0 to 18 years of age) in the condition of 'treatment of ureter and bladder carcinoma'.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.22. Empagliflozin - EMEA-000828-PIP06-18

Boehringer Ingelheim International GmbH; Treatment of chronic kidney disease

Day 60 Opinion

Uro-nephrology

Summary of committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agrees with the Applicant's request for a waiver. The PDCO recommends granting a waiver for empagliflozin for all subsets of the paediatric population (0 to less than18 years of age) in the condition of 'treatment of chronic kidney disease'.

2.1.23. Upadacitinib - EMEA-001741-PIP06-18

AbbVie Ltd; Treatment of vasculitides

Day 30 opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

Based on the assessment of this application the PDCO agrees with the Applicant's request for a waiver. The PDCO recommends granting a waiver for upadacitinib for all subsets of the paediatric population (0 to 18 years of age) in the condition of 'treatment of vasculitides' on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.
The PDCO emphasises that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need.

2.2. Opinions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance.

2.2.1. Avibactam / ceftazidime - EMEA-C2-001313-PIP01-12-M08

Pfizer Limited; Treatment of infections due to aerobic Gram-negative organisms

Day 30 letter

Infectious Diseases

Summary of committee discussion:

The PDCO discussed the completed studies and considered that these studies are compliant with the latest Agency's Decision (P/0340/2018) of 08 November 2018.
The PDCO finalised this partially completed compliance procedure on 1 February 2019.

2.2.2. Pembrolizumab - EMEA-C-001474-PIP01-13-M01

Merck Sharp & Dohme (Europe), Inc.; Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue)

Day 30 Opinion

Oncology

Summary of committee discussion:

The PDCO therefore considered that the study was compliant with the latest Agency's Decision P/0043/2018 of 16 February 2018. The PDCO took note of outcomes of preceding partial compliance check procedures: EMEA-C1-001474-PIP01-13.
The PDCO adopted on 01 February 2019 an Opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision P/0043/2018 of 16 February 2018.

2.2.3. Rituximab - EMEA-C-000308-PIP02-11-M01

Roche Registration GmbH; Treatment of microscopic polyangiitis

Day 30 Opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

The PDCO adopted on 1 February 2019 an Opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0060/2016) of 18 March 2016.

2.2.4. Rabeprazole (sodium) - EMEA-C-000055-PIP01-07-M06

Eisai Ltd.; Treatment of gastro-oesophageal reflux disease

Day 30 Opinion

Gastroenterology-Hepatology

Summary of committee discussion:

The PDCO adopted on 01 February 2019 an Opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0401/2018) of 03 December 2018.

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan

2.3.1. Ambrisentan - Orphan - EMEA-000434-PIP01-08-M05

Glaxo Group Limited; Treatment of pulmonary arterial hypertension / Idiopathic (IPAH) and familial (FPAH) pulmonary hypertension; Associated pulmonary hypertension (APAH)

Day 60 Opinion

Cardiovascular Diseases

Summary of committee discussion:

In conclusion, the PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency’s latest decision (P/0322/2016 of 02/12/2016).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.2. Tralokinumab - EMEA-001900-PIP02-17-M02

LEO Pharma A/S; Treatment of Atopic Dermatitis

Day 60 Opinion

Dermatology

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that all proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency’s latest decision (P/0250/2018 of 15 August 2018).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.3. Alogliptin benzoate (as alogliptin) - EMEA-000496-PIP01-08-M06

Takeda Development Centre Europe Ltd; Type 2 diabetes mellitus

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed

paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0255/2016 of 05/10/2016).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.4. Avalglucosidase alfa - Orphan - EMEA-001945-PIP01-16-M01

Genzyme Europe B.V.; ICD-10: E74.0; Glycogen storage disease (Pompe disease) / Long-term use as an ERT for the treatment of patients with a confirmed diagnosis of Pompe disease (acid α-glucosidase deficiency)

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0075/2017 of 17/03/2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.5. Tofacitinib - EMEA-000576-PIP03-12-M02

Pfizer Limited; Ulcerative colitis / Treatment of children and adolescents aged 2 to <18 years of age with moderate to severe ulcerative colitis.

Day 60 Opinion

Gastroenterology-Hepatology

Summary of committee discussion:

The PDCO's view expressed at Day 30 was re-discussed and endorsed. The PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0275/2018 of 31 August 2018).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.6. Ustekinumab - EMEA-000311-PIP04-13-M01

Janssen-Cilag International NV; Crohn's Disease / Treatment of Crohn's Disease

Day 60 Opinion

Gastroenterology-Hepatology

Summary of committee discussion:

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0045/2014 of 7 March 2014).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.7. Crizanlizumab - Orphan - EMEA-002141-PIP01-17-M01

Novartis Europharm Limited; Treatment of sickle cell disease / Prevention of vaso-occlusive crises in patients with sickle cell disease

Day 60 Opinion

Haematology-Hemostaseology

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

2.3.8. Apremilast - EMEA-000715-PIP02-11-M03

Celgene Europe B.V.; Treatment of juvenile idiopathic arthritis (JIA), Treatment of juvenile psoriatic arthritis (JPsA) / Treatment of juvenile psoriatic arthritis (JPsA)

Day 60 Opinion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0166/2015 of 07/08/2015).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.9. Isavuconazonium (sulfate) - Orphan - EMEA-001301-PIP02-12-M03

Basilea Pharmaceutica International Ltd.; Treatment of mucormycosis, Treatment of invasive aspergillosis

Day 60 Opinion

Infectious Diseases

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0314/2018 of 12 September 2018).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.10. EMEA-001838-PIP01-15-M02

Janssen-Cilag International NV; Treatment of respiratory tract disease caused by human respiratory syncytial virus (RSV)

Day 60 Opinion

Infectious Diseases

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0118/2017 of 5 May 2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.11. Lefamulin - EMEA-002075-PIP01-16-M01

Nabriva Therapeutics AG; Treatment of community-acquired pneumonia

Day 60 Opinion

Infectious Diseases

Summary of committee discussion:

The PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0241/2017 of 04 September 2017).

2.3.12. Erenumab - EMEA-001664-PIP02-15-M03

Novartis Europharm Limited; Prevention of migraine headaches / Prophylaxis of migraine

Day 60 Opinion

Neurology

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0068/2018 of 16/3/2018).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.13. Galcanezumab - EMEA-001860-PIP03-16-M02

Eli Lilly and Company Limited; Prevention of migraine headaches

Day 60 Opinion

Neurology

Summary of committee discussion:

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0137/2018 of 7/5/2018).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.14. Satralizumab (humanised anti-IL-6 receptor (IL-6R) monoclonal antibody) - Orphan - EMEA-001625-PIP01-14-M02

CHUGAI PHARMA EUROPE LTD.; Treatment of neuromyelitis optica

Day 60 Opinion

Neurology

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0026/2017 of 27 January 2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.15. Lacosamide - EMEA-000402-PIP03-17-M03

UCB Pharma S.A.; Treatment of generalized epilepsy and epilepsy syndromes: Epilepsy - generalized idiopathic epilepsy and epilepsy syndromes [G40.3] Epilepsy - Other generalized epilepsy and epileptic syndromes [G40.4] / Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in paediatric patients with idiopathic generalized epilepsy (IGE)(4 years to <18 years)

Day 60 opinion

Neurology

Summary of committee discussion:

The PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0048/2018 of 22/02/2018).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.16. Peginterferon beta-1a - EMEA-001129-PIP01-11-M03

Biogen Idec Ltd; Multiple sclerosis / Treatment of relapsing remitting forms of multiple sclerosis

Day 60 opinion

Neurology

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0127/2018 of 11/04/2018).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.17. Acalabrutinib - Orphan - EMEA-001796-PIP03-16-M01

Acerta Pharma, BV; Treatment of mature B cell neoplasms / Treatment of children from 1 to <18 years of age with previously untreated mature B-cell neoplasms (e.g., diffuse large B-cell lymphoma [DLBCL], Burkitt lymphoma [BL] and primary mediastinal B-cell lymphoma [PMBCL]). Treatment of children from 1 to <18 years of age with relapsed/refractory mature B-cell neoplasms (e.g., diffuse large B-cell lymphoma [DLBCL], Burkitt lymphoma [BL] and primary mediastinal B-cell lymphoma [PMBCL]).

Day 60 opinion

Oncology

Summary of committee discussion:

In conclusion, based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0309/2017 of 30 October 2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.18. Dabrafenib mesylate - EMEA-001147-PIP01-11-M06

Novartis Europharm Limited; Treatment of solid malignant tumours (excluding melanoma), Treatment of melanoma / Treatment of paediatric patients with solid malignant tumours containing BRAF V600 mutations, Treatment of adolescent patients with melanoma with a BRAF V600 mutation

Day 60 Opinion

Oncology

Summary of committee discussion:

In conclusion, based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0260/2017 of 04/09/2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.19. Carotuximab - Orphan - EMEA-002138-PIP01-17-M01

TRACON Pharma Limited; Treatment of soft tissue sarcoma

Day 60 Opinion

Oncology

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as

set in the Agency's latest decision (P/0383/2017 of 19/12/2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.20. Olaratumab - Orphan - EMEA-001760-PIP01-15-M03

Eli Lilly and Company Limited; Treatment of soft tissue sarcoma, Treatment of osteosarcoma / Treatment of recurrent rhabdomyosarcoma in children aged from birth to less than 18 years in combination with a standard-of-care chemotherapy regimen, First-line treatment of osteosarcoma in children aged from 5-18 years in combination with a standard-of-care chemotherapy regimen

Day 60 Opinion

Oncology

Summary of committee discussion:

The PDCO granted a waiver on its motion for the condition 'treatment of soft tissue sarcoma' based on the ground that the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).
In conclusion, the PDCO adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0139/2017 of 07 June 2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.21. Rituximab - EMEA-000308-PIP01-08-M04

Roche Registration GmbH; Treatment of diffuse large B-cell lymphoma, Treatment of autoimmune arthritis / Treatment of mature B-cell malignancies, that is, diffuse large B-cell lymphoma, Burkitt and Burkitt-like lymphoma/leukaemia, Agreed waiver for all subsets of the paediatric population from birth to less than 18 years of age.

Day 60 Opinion

Oncology

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.

2.3.22. Trametinib dimethyl sulfoxide - EMEA-001177-PIP01-11-M05

Novartis Europharm Limited; Treatment of solid malignant tumours (excluding melanoma), Treatment of melanoma / Treatment of paediatric patients with solid malignant tumours containing BRAF V600 mutations, Treatment of adolescent patients with melanoma with a BRAF V600 mutation

Day 60 Opinion

Oncology

Summary of committee discussion:

In conclusion, based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0259/2017 of 04/09/2017).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.23. Eltrombopag (eltrombopag olamine) - EMEA-000170-PIP02-10-M03

Novartis Europharm limited; Secondary thrombocytopenia / Treatment of thrombocytopenia secondary to treatment of myeloid or lymphoid malignancies or solid tumours

Day 60 Opinion

Oncology / Haematology-Hemostaseology

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant, the PDCO considered that the proposed changes of modifying the previous PIP into a full waiver based on likely lack of efficacy are acceptable.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0007/2015 of 30/01/2015).
The new PDCO Opinion on the modified agreed full waiver supersedes the previous PDCO PIP Opinion.

2.3.24. Autologous cartilage derived cultured chondrocytes - EMEA-001823-PIP01-15-M01

TETEC AG; Treatment of cartilage disorders

Day 60 opinion

Other

Summary of committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision P/0242/2016 of 9 September 2016).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.25. Methoxyflurane - EMEA-000334-PIP01-08-M08

Medical Developments UK Ltd; Treatment of acute pain / Self administration to conscious patients with minor trauma and associated pain, under supervision of personnel trained in its use, For the management of acute pain associated with short surgical procedures, such as the change of dressings, dislocations and injections

Day 60 Opinion

Pain

Summary of committee discussion:

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0110/2018 of 11/4/2018).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.26. Chemically modified extract of grass pollen from Holcus lanatus, Phleum pratense and Poa pratensis - EMEA-001016-PIP01-10-M01

Granzer Regulatory Consulting & Services; Allergic Rhinitis / Allergic Rhinitis, Allergic Rhinoconjunctivitis

Day 60 Opinion

Pneumology - Allergology / Oto-rhino-laryngology

Summary of committee discussion:

The PDCO, therefore, adopted a negative Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/147/2011 of 09/06/2011).

2.3.27. Chemically modified extract of grass pollen from Holcus lanatus, Phleum pratense and Poa pratensis - EMEA-001017-PIP01-10-M01

Granzer Regulatory Consulting & Services; Allergic Rhinitis / Allergic Rhinitis, Allergic Rhinoconjunctivitis

Day 60 Opinion

Pneumology - Allergology / Oto-rhino-laryngology

Summary of committee discussion:

The PDCO, therefore, adopted a negative Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/148/2011 of 09/06/2011).

2.3.28. Chemically modified extract of trees pollen from Birch and Alder - EMEA-001012-PIP01-10-M01

Granzer Regulatory Consulting & Services; Allergic Rhinitis / Allergic Rhinitis, Allergic Rhinoconjunctivitis

Day 60 Opinion

Pneumology - Allergology / Oto-rhino-laryngology

Summary of committee discussion:

The PDCO, therefore, adopted a negative Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/143/2011 of 09/06/2011).

2.3.29. Chemically modified extract of trees pollen from Birch and Alder - EMEA-001013-PIP01-10-M01

Granzer Regulatory Consulting & Services; Allergic Rhinitis / Allergic Rhinitis, Allergic Rhinoconjunctivitis

Day 60 Opinion

Pneumology - Allergology / Oto-rhino-laryngology

Summary of committee discussion:

The PDCO adopted a negative Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/144/2011 of 09 June 2011).

2.3.30. Chemically modified house dust mites allergen extract of Dermatophagoides pteronyssinus and Dermatophagoides farinae - EMEA-001011-PIP01-10-M01

Granzer Regulatory Consulting & Services; Allergic Rhinitis / Allergic Rhinitis, Allergic Rhinoconjunctivitis

Day 60 Opinion

Pneumology - Allergology / Oto-rhino-laryngology

Summary of committee discussion:

The PDCO adopted a negative Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/142/2011 of 09 June 2011).

2.3.31. Chemically modified house dust mites allergen extract of Dermatophagoides pteronyssinus and Dermatophagoides farinae - EMEA-001014-PIP01-10-M01

Granzer Regulatory Consulting & Services; Allergic Rhinitis / Allergic Rhinitis, Allergic Rhinoconjunctivitis

Day 60 Opinion

Pneumology - Allergology / Oto-rhino-laryngology

Summary of committee discussion:

The PDCO adopted a negative Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/145/2011 of 09 June 2011).

2.3.32. Neisseria meningitidis serogroup B recombinant lipoprotein (subfamily B; Escherichia coli) / Neisseria meningitidis serogroup B recombinant lipoprotein (subfamily A; Escherichia coli) - EMEA-001037-PIP02-11-M05

Pfizer Europe MA EEIG; Invasive meningococcal disease caused by N meningitidis serogroup B.

Day 60 Opinion

Vaccines

Summary of committee discussion:

Based on the review of the rationale submitted by the Applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0013/2017 of 31 January 2017).

The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.33. Upadacitinib - EMEA-001741-PIP02-16-M01

AbbVie Ltd; Treatment of Ulcerative Colitis

Day 30 Opinion

Immunology-Rheumatology-Transplantation / Gastroenterology-Hepatology

Summary of committee discussion:

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0022/2018 of 30 January 2018).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.34. Upadacitinib - EMEA-001741-PIP03-16-M01

AbbVie Ltd; Treatment of Crohn's disease

Day 30 Opinion

Immunology-Rheumatology-Transplantation / Gastroenterology-Hepatology

Summary of committee discussion:

The PDCO therefore adopted a favourable Opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0046/2018 of 16 February 2018).
The new PDCO Opinion on the modified agreed PIP supersedes the previous PDCO Opinion.

2.3.35. Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H3N2) / Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Yamagata lineage) / Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Victoria lineage) / Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H1N1) (EMEA-001715-PIP01-14-M02)

Seqirus Netherlands B.V.; Prevention of influenza infection

Opinion adopted via written procedure

Vaccines

Summary of committee discussion:

The final Opinion has been sent to the PDCO for comments in writing. The final Opinion has been agreed and adopted via written procedure on 12 February 2019.

2.4. Opinions on Re-examinations

2.4.1. Empagliflozin - EMEA-000828-PIP04-16-M02

Boehringer Ingelheim International GmbH; Treatment of type 1 diabetes mellitus

Day 30 Opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of committee discussion:

During its January 2019 plenary meeting (29 January – 01 February 2019), the PDCO discussed the re-examination request for EMEA-000828 – PIP04-16-M02. The PDCO therefore confirmed the Opinion adopted at the previous PDCO plenary meeting on 14 December 2018.

2.5. Opinions on Review of Granted Waivers

No items

2.6. Finalisation and adoption of opinions

No items

2.7. Partial Compliance Checks completed by EMA

For the following partial compliance checks, no need to refer them to PDCO Committee for discussion, were identified by the PME coordinator and PDCO Rapporteur. The PDCO has been informed in writing.

2.7.1. Pembrolizumab - EMEA-C1-001474-PIP02-16-M01

Merck Sharp & Dohme (Europe), Inc.; Treatment of Hodgkin lymphoma

Day 1 letter

Oncology

Summary of committee discussion:

Initiation of Study is hereby confirmed to be compliant as set out in the EMA's Decision P/0008/2018 of 30 January 2018.

2.7.2. Venetoclax - EMEA-C1-002018-PIP02-16-M01

AbbVie Limited; Treatment of haematopoietic and lymphoid malignant neoplasms

Day 30 letter

Oncology

Summary of committee discussion:

The partial compliance check has been finalised with a confirmation of compliance of all those studies contained in the agreed paediatric investigation plan that were subject of this procedure.

2.7.3. Edoxaban (tosylate) - EMEA-C3-000788-PIP02-11-M08

Daiichi Sankyo Europe GmbH; Prevention of venous thromboembolism

Day 1 letter

Cardiovascular Diseases / Haematology-Hemostaseology

Summary of committee discussion:

Study(ies) listed are hereby confirmed to be compliant as set out in the EMA's Decision (P/0368/2018) of 07 December 2018.
The partial compliance check has been finalised with a confirmation of compliance of all those studies contained in the agreed paediatric investigation plan that were subject of this procedure.

2.7.4. Baricitinib - EMEA-C1-001220-PIP03-16

Eli Lilly and Company; Treatment of atopic dermatitis

Day 30 discussion

Immunology-Rheumatology-Transplantation

Summary of committee discussion:

Study is hereby confirmed to be compliant as set out in the EMA's Decision P/0291/2018 of 12 September 2018.
The partial compliance check has been finalised with a confirmation of compliance of all those studies contained in the agreed paediatric investigation plan that were subject of this procedure.
The PDCO has been informed about the outcome.

2.7.5. Eculizumab - EMEA-C1-000876-PIP03-14-M02

Alexion Europe SAS; Treatment of neuromyelitis optica spectrum disorders

Day 30 discussion

Neurology

Summary of committee discussion:

Initiation of Study is hereby confirmed to be compliant as set out in the EMA's Decision P/0364/2018 of 06 December 2018.

3. Discussion of applications

Some information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Discussions on Products D90-D60-D30

3.1.1. EMEA-002378-PIP01-18

Treatment of acute heart failure

Day 90 discussion

Cardiovascular Diseases

3.1.2. Hepcidin-25 acetate (synthetic human hepcidin) - Orphan - EMEA-002083-PIP01-16

La Jolla Pharmaceutical II B.V.; Treatment of iron overload

Day 90 discussion

Endocrinology-Gynaecology-Fertility-Metabolism / Haematology-Hemostaseology

3.1.3. EMEA-001710-PIP03-17

Treatment of ulcerative colitis

Day 90 discussion

Gastroenterology-Hepatology

3.1.4. EMEA-002374-PIP01-18

Treatment of systemic lupus erythematosus (SLE)

Day 90 discussion

Immunology-Rheumatology-Transplantation

3.1.5. Voclosporin - EMEA-002264-PIP01-17

Treatment of Systemic Lupus Erythematosus / Treatment of Active Lupus Nephritis

Day 90 discussion

Immunology-Rheumatology-Transplantation

3.1.6. Oteseconazole - EMEA-002392-PIP01-18

Treatment of vulvovaginal candidiasis

Day 90 discussion

Infectious Diseases

3.1.7. Ofatumumab - EMEA-002397-PIP01-18

Treatment of multiple sclerosis / Treatment of relapsing remitting multiple sclerosis

Day 90 discussion

Neurology

3.1.8. Abemaciclib - EMEA-002342-PIP01-18

Ewing's sarcoma (ES) / Treatment of relapsed/refractory Ewing sarcoma in children and young adults, in combination with irinotecan and temozolomide

Day 90 discussion

Oncology

3.1.9. EMEA-002348-PIP01-18

B-cell Acute Lymphoblastic Leukemia / Treatment of relapse or refractory B-cell acute lymphoblastic leukemia

Day 90 discussion

Oncology

3.1.10. Autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector encoding a chimeric antigen receptor targeting human B cell maturation antigen with 4-1BB and CD3-zeta intracellular signaling domains - Orphan - EMEA-002369-PIP01-18

Celgene Europe B.V.; Treatment of mature B-cell neoplasms / Treatment of paediatric BCMA+ relapsed or refractory B non-Hodgkin lymphoma

Day 90 discussion

Oncology

3.1.11. Vinorelbine tartrate (liposomal) - EMEA-002365-PIP01-18

Treatment of rhabdomyosarcoma / Maintenance therapy after 1st relapse treatment, Treatment of relapsed or refractory rhabdomyosarcoma, Maintenance therapy for high-risk rhabdomyosarcoma patients achieving complete remission after frontline treatment

Day 90 discussion

Oncology

3.1.12. Aflibercept - EMEA-000236-PIP05-18

Retinopathy of prematurity (ROP) / Aflibercept is indicated for the treatment of retinopathy of prematurity (ROP)

Day 90 discussion

Ophthalmology

3.1.13. Nintedanib - Orphan - EMEA-001006-PIP05-18

Boehringer Ingelheim International GmbH; Treatment of fibrosing Interstitial Lung Diseases (ILD) / Treatment of fibrosing Interstitial Lung Diseases (ILD) in paediatric patients

Day 90 discussion

Pneumology - Allergology / Oncology

3.1.14. EMEA-002307-PIP01-17

Prevention of Ebola Virus Disease / Prevention of EVD in children aged ≥1 year

Day 90 discussion

Vaccines / Infectious Diseases

3.1.15. EMEA-002308-PIP01-17

Prevention of Ebola Virus Disease / Prevention of EVD in children aged ≥1 year

Day 90 discussion

Vaccines / Infectious Diseases

3.1.16. EMEA-002451-PIP01-18

Alopecia Areata

Day 60 discussion

Dermatology

3.1.17. EMEA-002464-PIP01-18

Treatment of atopic dermatitis / Treatment of patients with moderate-to-severe atopic dermatitis

Day 60 discussion

Dermatology

3.1.18. Trifarotene cream HE1 - EMEA-001492-PIP02-18

Treatment of Lamellar Ichthyosis

Day 60 discussion

Dermatology

3.1.19. EMEA-002448-PIP01-18

Treatment of non-alcoholic steatohepatitis (NASH) / Treatment of NASH with moderate to severe liver fibrosis

Day 60 discussion

Gastroenterology-Hepatology

3.1.20. C1 esterase inhibitor (human) - EMEA-000568-PIP02-18

Hereditary angioedema / Treatment of hereditary angioedema

Day 60 discussion

Immunology-Rheumatology-Transplantation

3.1.21. Liposomal ciclosporin A (L-CsA) - Orphan - EMEA-002344-PIP02-18

Breath Therapeutics GmbH; Treatment of Bronchiolitis obliterans Syndrome (BOS)

Day 60 discussion

Immunology-Rheumatology-Transplantation

3.1.22. Baloxavir marboxil - EMEA-002440-PIP01-18

Prevention of Influenza, Treatment of Influenza / Treatment of influenza type A/B in otherwise healthy, high risk and hospitalised patients. Prevention (post exposure prophylaxis) of influenza type A/B. Reduction of transmission of influenza type A/B

Day 60 discussion

Infectious Diseases

3.1.23. Hydrocortisone - EMEA-002305-PIP01-17

Prevention of Bronchopulmonary dysplasia

Day 60 discussion

Neonatology - Paediatric Intensive Care

3.1.24. Padsevonil - EMEA-002466-PIP01-18

Treatment of focal-onset seizures (FOS) in patients with epilepsy / Treatment of FOS in paediatric patients (≥2 to <18 years of age) with epilepsy

Day 60 discussion

Neurology

3.1.25. Larotrectinib - Orphan - EMEA-001971-PIP03-18

Bayer AG; Treatment of malignant neoplasms of the central nervous system / Treatment of paediatric patients with a primary CNS tumour with a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion

Day 60 discussion

Oncology

3.1.26. Marizomib - EMEA-002452-PIP01-18

Treatment of malignant glial tumors / Treatment of patients (paediatric) with diffuse intrinsic pontine glioma (DIPG) who have received radiation therapy

Day 60 discussion

Oncology

3.1.27. aldesleukin - EMEA-002492-PIP01-18

Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoetic, and lymphoid tissue) / treatment of a relapsed or refractory paediatric malignant solid tumour in paediatric patients less than 18 years old, treatment of patients with unresectable or metastatic melanoma in the age group from 12 to less than 18 years old

Day 60 discussion

Oncology

3.1.28. Zanubrutinib - EMEA-002354-PIP02-18

Treatment of mature B-cell neoplasms excluding lymphoplasmacytic lymphoma (Waldenström's macroglobulinaemia), Treatment of lymphoplasmacytic lymphoma (Waldenström's macroglobulinaemia) / Treatment of primary mediastinal B-cell lymphoma, Treatment of Burkitt lymphoma, Treatment of diffuse large B-cell lymphoma

Day 60 discussion

Oncology

3.1.29. Pneumococcal Polyssacharide Serotype 33F conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 23F conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 22F conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 19F conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 19A conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 18C conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 15B conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 14 conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 12F conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 11A conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 10A conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 9V conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 8 conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 7F conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 6B conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 6A conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 5 conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 4 conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 3 conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate / Pneumococcal Polyssacharide Serotype 1 conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate - EMEA-002330-PIP01-18

Disease caused by Streptococcus pneumoniae

Day 60 discussion

Vaccines

3.1.30. Recombinant respiratory syncytial virus fusion (RSV F) glycoprotein - EMEA-001985-PIP01-18

Prevention of respiratory syncytial virus (RSV) disease in infants via maternal immunization / Prevention of respiratory syncytial virus (RSV) disease in infants via maternal immunization

Day 60 discussion

Vaccines

3.1.31. Rosuvastatin calcium / fenofibrate - EMEA-002509-PIP01-18

Mixed dislipidemia, i.e. hypertriglyceridemia combined with hypercholesterolemia

Day 30 discussion

Cardiovascular Diseases

3.1.32. EMEA-002481-PIP01-18

Moderate to severe atopic dermatitis

Day 30 discussion

Dermatology

3.1.33. Serlopitant - EMEA-002496-PIP01-18

Treatment of prurigo nodularis

Day 30 discussion

Dermatology

3.1.34. Gadopiclenol - EMEA-001949-PIP02-18

Diagnostic / Detection and visualization of disorders or lesions with suspected abnormal vascularity in various body regions

Day 30 discussion

Diagnostic

3.1.35. Levonorgestrel - EMEA-002474-PIP02-18

Contraception

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.36. Norursodeoxycholic acid - Orphan - EMEA-002485-PIP01-18

Dr. Falk Pharma GmbH; Primary sclerosing cholangitis (PSC)

Day 30 discussion

Gastroenterology-Hepatology

3.1.37. AAV2/S3-FRE1-TI-FIXco1 vector - Orphan - EMEA-002518-PIP01-18

Freeline Therapeutics Limited; Haemophilia B

Day 30 discussion

Haematology-Hemostaseology

3.1.38. Recombinant human monoclonal antibody against mannan-binding lectin-associated serine protease-2 - Orphan - EMEA-002479-PIP01-18

Omeros London Limited; Treatment in haematopoietic stem cell transplantation (HSCT) / Treatment of haematopoietic stem cell transplant associated thrombotic microangiopathy (HSCT-TMA).

Day 30 discussion

Haematology-Hemostaseology

3.1.39. Anti-CD7 mAb conjugated to ricin toxin A chain (WT1-RTA) / anti-CD3 mAb conjugated to ricin toxin A chain (SPV-T3a-RTA) - Orphan - EMEA-002087-PIP01-16

Xenikos BV; Steroid refractory acute graft versus host disease

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.40. Secukinumab - EMEA-000380-PIP05-18

Hidradenitis suppurativa

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.41. Artesunate - Orphan - EMEA-002402-PIP02-18

ACE Pharmaceuticals BV; Plasmodia infections / Treatment of severe malaria caused by Plasmodium falciparum in children aged 1 month to 18 years

Day 30 discussion

Infectious Diseases

3.1.42. Delafloxacin - EMEA-001080-PIP03-18

Treatment of community acquired pneumonia (CAP)

Day 30 discussion

Infectious Diseases

3.1.43. Equine Immunoglobulin F(ab')2 fragments targeting Shiga toxin - Orphan - EMEA-002444-PIP02-18

Chemo Research, S.L.; Prevention of Shiga-Toxin Producing Escherichia Coli Haemolytic Uremic Syndrome

Day 30 discussion

Infectious Diseases

3.1.44. Tazobactam sodium / cefepime hydrochloride - EMEA-002483-PIP01-18

Treatment of complicated urinary tract infections (cUTI)

Day 30 discussion

Neonatology - Paediatric Intensive Care / Infectious Diseases / Uro-nephrology

3.1.45. EMEA-002419-PIP02-18

Prostate-specific membrane antigen (PSMA)-expressing metastatic, castration-resistant, prostate cancer

Day 30 discussion

Oncology

3.1.46. Crizotinib - EMEA-001493-PIP03-18

Anaplasic lymphoma kinase (ALK)-positive inflammatory myofibroblastic tumour (IMT), ALK-positive anaplastic large cell lymphoma (ALCL) / Treatment of paediatric patients with relapsed/refractory systemic ALK-positive ALCL, Treatment of paediatric patients with unresectable or relapsed/refractory ALK-positive IMT

Day 30 discussion

Oncology

3.1.47. Flucytosine - Orphan - EMEA-002437-PIP02-18

Tocagen Inc; Treatment of glioma

Day 30 discussion

Oncology

3.1.48. L-asparaginase - Orphan - EMEA-000341-PIP03-18

ERYTECH Pharma S.A.; Treatment of pancreatic cancer

Day 30 discussion

Oncology

3.1.49. Rivoceranib mesylate - Orphan - EMEA-002489-PIP01-18

LSK BioPharma Limited; Treatment of gastric cancer / Treatment of adult patients with advanced or metastatic gastric cancer

Day 30 discussion

Oncology

3.1.50. Rogaratinib - EMEA-002439-PIP01-18

Treatment of urothelial carcinoma

Day 30 discussion

Oncology

3.1.51. EMEA-002504-PIP01-18

Treatment of all conditions included in the category of malignant neoplasms expressing CEACAM5 protein

Day 30 discussion

Oncology

3.1.52. Tislelizumab - EMEA-002480-PIP01-18

Treatment of all conditions included in the category of malignant neoplasms (except central nervous system, haematopoietic and lymphoid tissue)

Day 30 discussion

Oncology

3.1.53. Vocimagene amiretrorepvec - Orphan - EMEA-002505-PIP02-18

Tocagen Inc.; Treatment of glioma

Day 30 discussion

Oncology

3.1.54. Cenergermin - Orphan - EMEA-001729-PIP02-18

Dompé farmaceutici S.p.A.; Treatment of dry eye disease

Day 30 discussion

Ophthalmology

3.1.55. EMEA-002484-PIP01-18

Asthma / Use as an add-on controller medication in the treatment of adults, adolescents and children (>5 years of age) with inadequately controlled asthma

Day 30 discussion

Pneumology - Allergology

3.1.56. Orvepitant - EMEA-002510-PIP01-18

Treatment of refractory chronic cough

Day 30 discussion

Pneumology - Allergology

3.1.57. Synthetic double-stranded siRNA oligonucleotide directed against lactate dehydrogenase A mRNA and containing four modified nucleosides which form a ligand cluster of four N-acetylgalactosamine residues - Orphan - EMEA-002493-PIP01-18

Dicerna EU Limited; treatment primary hyperoxaluria

Day 30 discussion

Uro-nephrology

3.2. Discussions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

3.2.1. Sebelipase alfa - EMEA-C-001331-PIP01-12-M02

Alexion Europe SAS; Treatment of Lysosomal acid lipase deficiency

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism / Gastroenterology-Hepatology

3.2.2. Denosumab - EMEA-C-000145-PIP01-07-M09

Amgen Europe B.V.; Treatment of giant cell tumour of bone

Day 30 discussion

Oncology

3.2.3. Conestat Alfa - EMEA-C-000367-PIP01-08-M08

Pharming Group N.V.; Treatment of hereditary angioedema (HAE)

Day 30 discussion

Other

3.2.4. Peanut allergen extract - EMEA-C1-001481-PIP01-13-M03

DBV Technologies S.A.; Treatment of peanut allergy

Day 30 discussion

Pneumology - Allergology

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

3.3.1. Corifollitropin alfa - EMEA-000306-PIP01-08-M04

Merck Sharp & Dohme B.V.; Inability to achieve pregnancy, Treatment of hypogonadotrophic hypogonadism / female adults, boys

Day 30 discussion

3.3.2. Rivaroxaban - EMEA-000430-PIP01-08-M11

Bayer AG; Treatment of thromboembolic events, Prevention of thromboembolic events / Treatment (secondary prevention) of venous thromboembolism

Day 30 discussion

Cardiovascular Diseases

3.3.3. Ertugliflozin L-PGA[2] - EMEA-001533-PIP01-13-M02

Merck Sharp & Dohme (Europe), Inc.; Treatment of type 2 diabetes mellitus / Treatment of type 2 diabetes mellitus

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.4. Migalstat hydrochloride - Orphan - EMEA-001194-PIP01-11-M04

Amicus Therapeutics UK Limited; Treatment of Fabry disease

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.5. Recombinant parathyroid hormone: rhPTH (1-84) - Orphan - EMEA-001526-PIP01-13-M03

Shire Pharmaceuticals Ireland Limited; Hypoparathyroidism / Treatment of hypoparathyroidism

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.6. Luspatercept - Orphan - EMEA-001521-PIP01-13-M03

Celgene Europe B.V.; Anaemias due to chronic disorders / Treatment of anaemia in patients with beta-thalassemia intermedia and major

Day 30 discussion

Haematology-Hemostaseology

3.3.7. Nonacog beta pegol (glycopegylated recombinant coagulation factor IX) - Orphan - EMEA-000731-PIP01-09-M03

Novo Nordisk A/S; ICD10-D67-Hereditary factor IX deficiency / Treatment and prophylaxis of bleeding in patient with Haemophilia B (congenital factor IX deficiency)

[2] L-pyroglutamic acid

Day 30 discussion

Haematology-Hemostaseology

3.3.8. Roxadustat - EMEA-001557-PIP01-13-M03

Astellas Pharma Europe B.V.; treatment of anaemia due to chronic disorders

Day 30 discussion

Haematology-Hemostaseology

3.3.9. Tofacitinib citrate - EMEA-000576-PIP01-09-M10

Pfizer Limited; Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and juvenile idiopathic arthritis) / Juvenile idiopathic arthritis

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.3.10. Ceftolozane / tazobactam - EMEA-001142-PIP01-11-M03

Merck Sharp & Dohme (Europe), Inc.; Treatment of abdominal and gastrointestinal infections, Treatment of urinary tract infections / Treatment of complicated urinary tract infections (cUTI), Treatment of complicated intra-abdominal infections (cIAI)

Day 30 discussion

Infectious Diseases

3.3.11. Etravirine - EMEA-000222-PIP01-08-M09

Janssen-Cilag International NV; Treatment of HIV-1 virus infection / in combination with boosted protease inhibitor and other antiretroviral medicinal products for the treatment of HIV-1 infection in antiretroviral treatment-experienced adolescents and children from 2 months of age and older

Day 30 discussion

Infectious Diseases

3.3.12. Oritavancin diphosphate - EMEA-001270-PIP01-12-M02

Rempex London Ltd; Treatment of skin and subcutaneous tissue bacterial infections

Day 30 discussion

Infectious Diseases

3.3.13. Inebilizumab - Orphan - EMEA-001911-PIP01-15-M02

Viela Bio; Neuromyelitis optica spectrum disorder (NMOSD)

Day 30 discussion

Neurology

3.3.14. Teriflunomide - EMEA-001094-PIP01-10-M05

Genzyme Europe B.V. / Sanofi-Aventis groupe; Multiple sclerosis / Treatment of children and adolescents from 10 to less than 18 years of age with relapsing forms of Multiple sclerosis

Day 30 discussion

Neurology

3.3.15. Regorafenib - EMEA-001178-PIP01-11-M04

Bayer AG; Treatment of all conditions contained in the category of malignant neoplasms (except haematopoietic and lymphoid tissue) / Treatment of paediatric patients with a solid malignant tumour(s) integrated with anti-cancer therapy

Day 30 discussion

Oncology

3.3.16. Idarucizumab - EMEA-001438-PIP01-13-M01

Boehringer Ingelheim international GmbH; Prevention of dabigatran associated haemorrhage / Treatment of dabigatran associated haemorrhage

Day 30 discussion

Other

3.3.17. Selexipag - EMEA-000997-PIP01-10-M02

Janssen Cilag International NV; pulmonary arterial hypertension / Treatment of pulmonary arterial hypertension

Day 30 discussion

Other

3.3.18. Fevipiprant - EMEA-001315-PIP02-16-M01

Novartis EuroPharm Limited; Asthma / Treatment of uncontrolled persistent asthma

Day 30 discussion

Pneumology - Allergology

3.3.19. Peanut flour - EMEA-001734-PIP01-14-M04

Aimmune Therapeutics Inc; Peanut Allergy / Peanut oral immunotherapy for the reduction in clinical reactivity to accidental exposure in peanut children and adults

Day 30 discussion

Pneumology - Allergology

3.3.20. Neisseria meningitidis serogroup Y polysaccharide conjugated to tetanus toxoid / Neisseria meningitidis serogroup W-135 polysaccharide conjugated to tetanus toxoid / Neisseria meningitidis serogroup C polysaccharide conjugated to tetanus toxoid / Neisseria meningitidis serogroup A polysaccharide conjugated to tetanus toxoid - EMEA-001930-PIP01-16-M01

Sanofi Pasteur; Prevention of meningococcal disease

Day 30 discussion

Vaccines

4. Nominations

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

4.1. List of letters of intent received for submission of applications with start of procedure 01 April 2019 for Nomination of Rapporteur and Peer reviewer

Summary of committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver.

Summary of committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.3. Nominations for other activities

No items

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.2. Ongoing Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.3. Final Scientific Advice (Reports and Scientific Advice letters)

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6. Discussion on the applicability of class waivers

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Discussions on the applicability of class waiver for products

6.1.1. Humanized anti-tau monoclonal antibody-EMEA-17-2018

Roche Registration GmbH; All classes of medicinal products for treatment of Alzheimer's disease / Treatment of Alzheimer's disease

Summary of committee discussion:

The applicability of the class waiver as referred to in the Agency's Decision CW/0001/2015 to the planned therapeutic indication was confirmed.

Other potential paediatric interests of this medicine suggested by PDCO: None at this stage.

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver

No items

8. Annual reports on deferrals

The members of the PDCO took note of the products listed in the Annex B.

9. Organisational, regulatory and methodological matters

9.1. Mandate and organisation of the PDCO

9.1.1. PDCO Mandate

The PDCO Chair welcomed Tereza Bazantova, replacing Jaroslav Sterba, as the new

member for Czech Republic.
The PDCO Chair welcomed Petra Dominikova, replacing Peter Szitanyi, as the new member alternate for Czech Republic.

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

Summary of committee discussion:

The PDCO members were informed about the final CHMP Opinions on medicinal products with recommended paediatric indications adopted in December 2018. These included Tobramycin PARI, Trecondi, Simponi and Sprycel. A new strength for Simponi, 45 mg/0.45 mL solution for injection was approved for paediatric use from 2 years of age.

The list of procedures with paediatric indications to be evaluated by the CHMP, starting in December 2018, was presented to the PDCO members.

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

9.3.1. Non-clinical Working Group: D30 Products identified

PDCO member: Karen van Malderen

Summary of committee discussion:

The Chair of the Non-clinical Working Group identified the products which will require Non-clinical Working Group (NCWG) evaluation and discussion.

9.3.2. Formulation Working Group

PDCO member: Brian Aylward

Summary of committee discussion:

The Chair of the Formulation Working Group (FWG) identified the products which will require Formulation Working Group evaluation and discussion.

9.3.3. Patients' and Consumers' Organisations (PCWP) and Healthcare Professionals' Organisations (HCPWP)

PCWP and HCPWP revised Rules of procedure

PCWP revised Mandate and composition

HCPWP revised Mandate and composition

Summary of committee discussion:

PCWP and HCPWP revised Rules of procedure, PCWP revised Mandate and composition and HCPWP revised Mandate and composition were adopted by the PDCO.

9.4. Cooperation within the EU regulatory network

9.4.1. European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA)

Summary of committee discussion:

The Committee was informed that Gunter Egger has been nominated as Co-chair of Enpr-EMA (effective from 1 January 2019 to 31 December 2021).

9.5. Cooperation with International Regulators

No items

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee

No items

9.7. PDCO work plan

No items

9.8. Planning and reporting

No items

10. Any other business

11. Breakout sessions

11.1.1. Paediatric oncology

Summary of committee discussion:

The group discussed topics related to currently ongoing paediatric oncology procedures.

11.1.2. Neonatology

Summary of committee discussion:

The neonatal group discussed PIP related issues as well as an overview of comments received during the public consultation on the concept paper with respect to revision of the neonatal guideline.

11.1.3. Inventory

Summary of committee discussion:

The inventory group continued discussion on the assessment of unmet needs for products discussed during the PDCO plenary meeting.

11.1.4. Systemic lupus erythematosus

Summary of committee discussion:

During the breakout session options for the strategic development through PIPs in this therapeutic area were discussed

The Chair thanked all participants and closed the meeting.

12. List of participants

List of participants including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the January 2019 PDCO meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Dirk Mentzer	Chair	Germany	No interests declared	
Karl-Heinz Huemer	Member	Austria	No interests declared	
Johanna Wernsperger	Alternate	Austria	No interests declared	
Koenraad Norga	Member (Vice-Chair)	Belgium	No participation in discussion, final deliberations and voting on:	Ambrisentan - Orphan - EMEA-000434-PIP01-08-M05 (D60 Opinion)
Karen Van Malderen	Alternate	Belgium	No interests declared	
Dimitar Roussinov	Member	Bulgaria	No restrictions applicable to this meeting	none identified
Georgios Savva	Member	Cyprus	No interests declared	
Tereza Bazantova	Member	Czech Republic	No interests declared	
Petra Dominikova	Alternate	Czech Republic	No interests declared	
Kirstine Moll Harboe	Member	Denmark	No interests declared	
Irja Lutsar	Member	Estonia	No interests declared	
Jana Lass	Alternate	Estonia	No interests declared	
Ann Marie Totterman	Member	Finland	No interests declared	
Pia Annunen	Alternate	Finland	No participation in discussion, final deliberations and voting on:	EMEA-002378-PIP01-18 (D90 discussion) EMEA-002448-PIP01-18 (D60 discussion)
Sylvie Benchetrit	Member	France	No interests declared	
Dominique Ploin	Alternate	France	No interests declared	
Sabine Scherer	Member	Germany	No interests	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
			declared	
Yuansheng Sun	Alternate	Germany	No interests declared	
Eleni Katsomiti	Member	Greece	No interests declared	
Anastasia Mountaki	Alternate	Greece	No interests declared	
Ágnes Gyurasics	Member (CHMP member)	Hungary	No interests declared	
Brian Aylward	Member	Ireland	No interests declared	
Sara Galluzzo	Member	Italy	No interests declared	
Alessandro Jenkner	Alternate	Italy	No interests declared	
Dina Apele-Freimane	Member	Latvia	No restrictions applicable to this meeting	none identified
Sigita Burokiene	Member	Lithuania	No interests declared	
Goda Vaitkeviciene	Alternate	Lithuania	No interests declared	
Carola de Beaufort	Member (CHMP alternate)	Luxembourg	No interests declared	
Herbert Lenicker	Alternate	Malta	No interests declared	
Maaike van Dartel	Member	Netherlands	No interests declared	
Siri Wang	Member	Norway	No interests declared	
Anette Solli Karlsen	Alternate	Norway	No interests declared	
Marek Migdal	Member	Poland	No interests declared	
Helena Fonseca	Member	Portugal	No interests declared	
Hugo Tavares	Alternate	Portugal	No interests declared	
Dana Gabriela Marin	Member (CHMP alternate)	Romania	No interests declared	
Peter Sisovsky	Member	Slovakia	No interests declared	
Stefan Grosek	Member	Slovenia	No interests declared	
Fernando de Andrés Trelles	Member	Spain	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Maria Jesus Fernández Cortizo	Alternate	Spain	No interests declared	
Ninna Gullberg	Member	Sweden	No interests declared	
Eva Agurell	Alternate	Sweden	No interests declared	
Angeliki Siapkara	Member	United Kingdom	No interests declared	
Martina Riegl	Alternate	United Kingdom	No interests declared	
Fernando Cabanas	Member	Healthcare Professionals' Representative	No interests declared	
Jorrit Gerritsen	Alternate	Healthcare Professionals' Representative	No interests declared	
Francesca Rocchi	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Catherine Cornu	Alternate	Healthcare Professionals' Representative	No restrictions applicable to this meeting	none identified
Johannes Taminiau	Member	Healthcare Professionals' Representative	No interests declared	
Doina Plesca	Alternate	Healthcare Professionals' Representative	No restrictions applicable to this meeting	none identified
Paola Baiardi	Alternate	Patients' Organisation Representative		
Dimitrios Athanasiou	Member	Patients' Organisation Representative	No interests declared	
Viviana Giannuzzi	Alternate	Patients' Organisation Representative	No restrictions applicable to this meeting	
Joelle Warlin	Expert - via telephone*	Belgium	No interests declared	
Flora Musuamba Tshinanu	Expert - via telephone*	Belgium	No interests declared	
Tom Lams	Expert - via telephone*	Belgium	No interests declared	
Shiva Ramroop	Expert - in person*	United Kingdom	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Eleni Gaki	Expert - in person*	United Kingdom	No interests declared	
Susanne Kaul	Expert - via telephone*	Germany	No interests declared	

* Experts were only evaluated against the agenda topics or activities they participated in

13. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Paediatric investigation plan (PIP) (section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs)
A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

Compliance checks (section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check)
A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

Modification of an Agreed Paediatric Investigation Plan (section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP)
The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate.
In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

Class waiver (section 6 Discussion on the applicability of class waiver)
As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived**.** For more information on the classes of diseases subject to waivers, see class waivers.

Annual reports on deferrals (section 8)
If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/